Rome

• A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended recruitment
  2023-510339-12-00 5 2024-11-11 acne vulgaris
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil … Ended recruitment
  2023-510342-24-00 5 2024-11-11 Acne vulgaris
• Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemo+immunotherapy in resectable e … Ended recruitment
  2023-509584-24-01 4 2024-11-06 Malignant Pleural Mesothelioma
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended recruitment
  2024-510753-10-00 5 2024-11-01 Prurigo Nodularis
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended recruitment
  2023-509300-14-00 5 2024-10-31 Severe hypertriglyceridemia (SHTG)
• Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended recruitment
  2024-511202-23-00 4 2024-10-31 Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in … Ended recruitment
  2023-508096-36-00 5 2024-10-30 atopic dermatitis
• Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended recruitment
  2022-501457-37-00 5 2024-10-28 Myeloid Leukemia in Children with Down Syndrome
• Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Ended recruitment
  2023-506049-52-00 4 2024-10-28 Follicular lymphoma
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru … Ended recruitment
  2022-502168-19-00 4 2024-10-22 chronic graft-versus-host disease
• A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended recruitment
  2024-510584-37-00 4 2024-10-22 Systemic Lupus Erythematosus
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL … Ended recruitment
  2024-511627-34-00 4 2024-10-17 Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)
• Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended recruitment
  2023-503383-17-01 5 2024-10-10 Female androgenetic alopecia
• A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho … Ended recruitment
  2024-511304-16-00 4 2024-10-10 Newly Diagnosed Advanced Stage Follicular Lymphoma
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended recruitment
  2023-503714-77-00 4 2024-10-01 Advanced Non-Small Cell Lung Cancer
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• A study to check the effect of satralizumab in children and adolescents living with Duchenne muscular dystrophy, to check if it is safe and … Ended recruitment
  2024-512383-65-00 4 2024-09-26 Duchenne Muscular Dystrophy (DMD)
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• PROSPER: clinical Phase 2 study to test how safe and effective is a new medicine called FNP-223 to slow disease progression of progressive s … Ended recruitment
  2023-510366-28-00 4 2024-09-25 Progressive supranuclear palsy (PSP)
• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Ra … Ended recruitment
  2022-502269-13-00 4 2024-09-24 Glioma
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended recruitment
  2024-511038-11-00 4 2024-09-24 advanced prostate cancer

Showing 1,177–1,200 of 2,096 trials